Vps34 in Pulmonary Hypertension: A Pathway to Safer, Stronger Lungs
Official title: Vascular Smooth Muscle Vps34 in Pulmonary Arterial Hypertension
Funded at State University of Ny,binghamton · NIH-11331310 · Data updated 2026-11-12
Aims to understand how a cellular pathway (Vps34) drives abnormal blood vessel remodeling in pulmonary hypertension and test strategies to slow or stop this process.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of Ny,binghamton NIH-funded |
| Lab location | 1 site (Binghamton, United States) |
| Project start | May 20, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $248,738 |
| NIH project number | 5R00HL166763-06 |
| Project ID | NIH-11331310 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pulmonary arterial hypertension or at risk for PAH who may benefit from future targeted therapies.
✕Less likely to help
No direct benefit during this preclinical/patient-derived lab study; outcomes may inform future trials.
What this research studies
This grant focuses on how the Vps34 pathway affects the growth and survival of cells lining the small pulmonary arteries, which can lead to dangerous remodeling in pulmonary hypertension. The research uses human cell models and rodent systems to study a specific signaling pathway and its effects on cell growth, survival, and vascular structure. By blocking Vps34 activity in lab models, the team hopes to reduce abnormal cell behavior and vascular remodeling that contribute to PAH, potentially informing future therapies. The findings could help identify new targets to prevent progression and improve heart function in PAH patients.
Why it matters
Potential benefit: If successful, the work could identify a new target for drugs that slow PAH progression and protect heart function.
How similar studies have gone: Preclinical studies have shown that targeting similar pathways can reduce abnormal cell growth in PAH models, supporting further exploration here.
Where this research is happening
-
State University of Ny,binghamton
Binghamton, United States Active
Researchers
- Principal investigator: Shen, Yuanjun — State University of Ny,binghamton
- Study coordinator: Shen, Yuanjun
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.